Paxlovid for COVID-19

This course will provide pharmacy professionals with knowledge on the appropriate use and prescribing of antivirals such as Paxlovid in the treatment of mild to moderate COVID-19. Participants will also learn more about Paxlovid’s drug interactions, potential side effects, and patient eligibility. 

$0.00

Description

Description:

In January 2022 Health Canada approved the use of oral antiviral Paxlovid (Nirmatrelvir/Ritonavir). Paxlovid is the first authorized oral COVID-19 medication for outpatient use and is used for the treatment of mild to moderate COVID-19 infection in patients who are at high risk of progressing to serious disease, including hospitalization or death and patients who have a positive result from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral test.

This educational program contains a recording of a live webinar which occurred on April 11, 2022. The course includes representatives from the Ministry of Health and Dr. Kelly Grindrod from the University of Waterloo, and will provide pharmacy professionals with knowledge on the appropriate use and prescribing of antivirals such as Paxlovid in the treatment of mild to moderate COVID-19. Participants will also learn more about Paxlovid’s drug interactions, potential side effects, and patient eligibility.

Learning objectives:

By the end of this course, you should be able to:  

  • Identify patients most likely to benefit from nirmatrelvir/ritonavir (PaxlovidTM) 
  • Assess patients for appropriateness of therapy 
  • Assess and manage drug interactions 
  • Counsel on common and rare but serious side effects 
  • Understand the advocacy work involved to ensure pharmacists were part of the distribution of Paxlovid in Ontario 

Course outline:

  • Module 1 – Paxlovid in Ontario Pharmacies
  • Module 2 – Advocacy at Work
  • Course Evaluation

Course at a glance:

  • 1.5 hours to complete
  • Not accredited
  • Online
  • Completion requirement: Review the material, feedback survey

Who should take this course:

Pharmacists and pharmacy team members.

Development Team:

  • Dr. Kelly Grindrod, University of Waterloo
  • Jen Belcher, VP Strategic initiatives and Membership, OPA
  • Dr. Daniel Warshafsky, Associate Chief Medical Officer of Health
  • Fredrika Scarth, Ontario Health